ICECURE MEDICAL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.07 USD | +0.94% |
|
+3.88% | -.--% |
| May. 28 | Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024 | |
| May. 28 | Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000 | MT |
Financials (USD)
| Sales 2024 * | 3.97M | Sales 2025 * | 7.97M | Capitalization | 48.93M |
|---|---|---|---|---|---|
| Net income 2024 * | -13M | Net income 2025 * | -13M | EV / Sales 2024 * | 12.3 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.14 x |
| P/E ratio 2024 * |
-3.82
x | P/E ratio 2025 * |
-4.06
x | Employees | 74 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on IceCure Medical Ltd
More recommendations
More press releases
| 1 day | +0.94% | ||
| 1 week | +3.88% | ||
| 1 month | -10.08% | ||
| 3 months | -18.32% | ||
| 6 months | -1.83% |
1 week
1.02
1.11
1 month
0.991.26
Current year
0.991.57
1 year
0.521.57
3 years
0.5212.40
5 years
0.0212.40
10 years
0.0212.40
| Managers | Title | Age | Since |
|---|---|---|---|
Eyal Shamir
CEO | Chief Executive Officer | 63 | 16-08-31 |
Ronen Tsimerman
DFI | Director of Finance/CFO | 54 | 17-04-30 |
Naum Muchnik
CTO | Chief Tech/Sci/R&D Officer | 47 | 18-03-24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 12-08-14 | |
Oded Tamir
BRD | Director/Board Member | 68 | 13-07-31 |
Chun Hung Chan
BRD | Director/Board Member | 61 | 22-12-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.07 | +0.94% | 37,633 |
| 24-05-30 | 1.06 | +2.91% | 40,405 |
| 24-05-29 | 1.03 | -0.96% | 81,537 |
| 24-05-28 | 1.04 | +0.97% | 144,935 |
| 24-05-24 | 1.03 | -0.96% | 88,933 |
Delayed Quote Nasdaq, May 31, 2024 at 03:54 pm EDT
More quotes
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.07
USD
Average target price
3.387
USD
Spread / Average Target
+216.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 48.93M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- ICCM Stock
